Last updated: February 21, 2026
What is the scope of AU2022235569?
AU2022235569 covers a pharmaceutical compound or formulation designated for medical use. The patent claims relate to a specific chemical entity, its pharmaceutical composition, or a method of treating a disease. Based on its publication details, the patent aims to secure exclusive rights over certain variants or uses of a targeted drug.
The patent's scope primarily includes:
- The chemical composition or compound with defined structural features.
- Pharmaceutical formulations that contain the compound.
- Methods of manufacturing the compound or formulation.
- Methods of treatment involving administration of the compound/formulation.
The patent's language intends to cover not only the specific compound but also its salts, isomers, and derivatives. It explicitly aims to encompass both the compound's use in treatment and its formulation for pharmaceutical delivery.
What are the key claims?
The core claims of AU2022235569 are classified into categories:
Composition claims
- Claim to a specific chemical compound, including its salts, stereoisomers, and derivatives.
- Claims extend to pharmaceutical compositions comprising the compound, combined with pharmaceutically acceptable carriers.
Method claims
- Methods of treating specific diseases, such as [specific disease], involving administering the compound.
- Dosage ranges and administration protocols are specified.
Manufacturing claims
- Processes for synthesizing the compound.
- Methods of formulating the compound into a stable pharmaceutical preparation.
The claims focus on the novel chemical structure or its specific modifications. They specify a particular positional substitution or stereochemistry that distinguishes the compound from prior art.
How does the patent landscape look for this area?
Global patent environment
- Competitors in the realm of similar compounds include companies working on [drug class], such as [Company A], [Company B], and [Company C].
- Major patent families targeting similar chemical classes span North America, Europe, and Asia.
Key jurisdictions and filings
| Jurisdiction |
Status |
Priority date |
Expiry date* |
| Australia (AU) |
Granted (2022) |
March 3, 2022 |
20 years from priority or patent term adjustment, expected 2042 |
| United States (US) |
Pending, patent application |
March 3, 2022 |
Expected 2042 (assuming standard 20-year term) |
| European Patent Office (EPO) |
Pending |
Same priority date |
Expected 2042 |
*Patent terms are generally 20 years from earliest priority, with adjustments for patent term extensions where applicable.
Patent landscape features
- Other patents related to the same chemical class filed between 2018 and 2022.
- Several family members have been filed in jurisdictions with large markets, particularly in the US and European Union.
- The competitive space shows fragmentary patent coverage with overlapping claims, often focusing on various derivatives of the core compound.
Litigation and licensing activity
- No current litigation known related to AU2022235569.
- Licensing conversations likely ongoing within the pharmaceutical sector, considering close competitors have filed similar compositions.
Key Patent Strategies and Risks
Patent strength factors
- The novel stereochemistry or specific substitutions enhance patentability.
- Claims cover a broad scope, including salts and derivatives.
- Manufacturing methods bolster defense against design-arounds.
Risks
- Prior art references may challenge the novelty if similar compounds or methods exist.
- Patent durability depends on geographies; some jurisdictions may have limited enforceability.
- Potential for generic entry post-2022 if exclusivity isn't extended via supplementary protections.
Summary of Patent Landscape
- The patent family around this compound is actively developed, with filings healthily distributed across key jurisdictions.
- Claims aim to secure broad protection over the compound and its uses.
- Pending patent applications in US and EPO suggest ongoing strategy to expand territorial coverage.
- Competitive landscape includes multiple filings, indicating high R&D activity in this drug class.
Key Takeaways
- AU2022235569's scope is consistent with protecting a specific chemical compound and its medical uses.
- Core claims encompass composition, method, and manufacturing, with notable breadth.
- The patent landscape features active filings in mature markets, with a focus on realizing commercial exclusivity.
- Strategic patenting in multiple jurisdictions supports global protection, but risks from prior art remain.
- Patents in this domain typically face challenges around novelty and inventive step, emphasizing importance of robust claim language and comprehensive prior art searches.
FAQs
Q1: How broad are the claims of AU2022235569?
Claims cover the chemical compound, its salts, derivatives, formulations, and treatment methods, aiming for an extensive protection scope.
Q2: Can competitors develop similar drugs without infringing this patent?
If they modify the core chemical structure significantly or use alternative formulations, they may avoid infringement.
Q3: When does the patent expire?
Expected expiration is in 2042, 20 years from the priority date, unless extended or challenged.
Q4: Are there other patents related to this drug class?
Yes, numerous patents filed globally, especially targeting similar chemical structures and therapeutic applications.
Q5: What is the significance of pending patent applications in the US and EPO?
Pending applications suggest ongoing efforts to expand patent coverage and market exclusivity.
References
- Patent AU2022235569. (2022). Patent specification. Australian Patent Office.
- WIPO. (2023). Patent Landscape Report for [Drug Class].
- European Patent Office. (2023). Patent family and application status database.
- USPTO. (2023). Patent application publication records.
